Welcome to our dedicated page for Rxsight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading RxSight’s SEC filings can feel like navigating both Wall Street ledgers and FDA rule books at once. Financial metrics sit beside ophthalmic device trial data, and key details about Light Adjustable Lens adoption hide deep within risk sections. Stock Titan’s AI turns that complexity into clarity in real time.
Rather than combing through a 300-page annual report, open our dashboard and see the exact pages where management discusses surgeon utilization or reimbursement trends. Our tool automatically surfaces:
- Highlights from every RxSight annual report 10-K simplified for revenue sources and regulatory milestones
- Segment trends inside each RxSight quarterly earnings report 10-Q filing with side-by-side comps
- RxSight 8-K material events explained minutes after they hit EDGAR
- RxSight insider trading Form 4 transactions and director purchases, plus Form 4 insider transactions real-time alerts
- Key vote items from the latest proxy statement executive compensation disclosures
Have a plain-language question like “How much did RxSight’s executives earn last year?” or “What changed in LAL gross margins?” Simply type it in—our engine is tuned for understanding RxSight SEC documents with AI. You’ll get an answer, the source paragraph, and a link straight to the filing.
Whether you’re tracking RxSight earnings report filing analysis before an investor call or monitoring executive stock transactions Form 4 for sentiment shifts, Stock Titan delivers the full filing set, continuously updated, without the technical jargon. Complex medical-device disclosures, explained simply.
Foundations Investment Advisors, LLC (FIA) has filed Amendment No. 5 to its Schedule 13G for the Hypatia Women CEO ETF (CUSIP 90214Q527), a series of the Two Roads Shared Trust. The filing, triggered as of 30 June 2025 and signed on 8 July 2025, discloses that FIA now reports zero shares beneficially owned, representing 0% of the outstanding class. FIA also reports no sole or shared voting or dispositive power over any shares.
Because beneficial ownership has fallen below the 5 % reporting threshold, FIA checks the box for “Ownership of 5 percent or less of a class” and lists itself under Item 3(e) as an investment adviser registered under Rule 13d-1(b)(1)(ii)(E).
The absence of any remaining position suggests a complete exit or reclassification of shares previously held. No other entities are listed, and there is no indication of group activity, subsidiary involvement, or pending transactions. Certifications are routine and the document contains no financial statements or earnings data.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
What is the primary focus of RxSight, Inc.?
How does the RxSight Light Adjustable Lens system work?
What are the main components of the RxSight product portfolio?
How does RxSight differentiate itself in the ophthalmic device market?
What benefits does light adjustability offer to patients after cataract surgery?
What is the significance of RxSight's integrated support for clinical practice?
In what ways does RxSight emphasize research and development?
How does RxSight maintain its competitive position in a crowded market?
